Table of Content

1. Report Overview
1.1 Global Blood Cancer Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.8.1 Primary Research
1.8.2 Secondary Research
1.8.3 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)

2. The Global Blood Cancer Market by Therapy Area: Incident Cases by Country 2018-2018
2.1 Overview of Blood Cancer
2.2 Signs and Symptoms
2.3 Causes of Blood Cancer
2.4 Blood Cancer Treatment & Therapy Options
2.5 Leukaemia
2.5.1 Acute Lymphocytic Leukaemia (ALL) in Adults
2.5.2 Acute Myeloid Leukaemia (AML)
2.5.3 Chronic Lymphocytic Leukaemia (CLL)
2.5.4 Chronic Myeloid Leukaemia (CML)
2.5.5 Chronic Myelomonocytic Leukaemia
2.5.6 Leukaemia in Children
2.5.7 Survival
2.6 Lymphoma
2.6.1 Non-Hodgkin lymphomas
2.6.2 Hodgkin disease
2.6.3 Survival
2.7 Myeloma
2.7.1 Survival

3. The Global Blood Cancer Market by Type of Therapy: Market Forecast to 2028
3.1 An Introduction to Various Types of Therapies
3.2 Chemotherapy
3.2.1 Global Chemotherapy Market Forecast to 2028
3.3.1 Global Targeted Therapy Market Forecast to 2028
3.4 Immunotherapy
3.4.1 Global Immunotherapy Market Forecast to 2028

4. Global Blood Cancer Market by Region: Market Forecast to 2028
4.1 An Introduction to the Market Geography
4.2 United States Blood Cancer Market Forecast to 2028
4.2.1 United States Blood Cancer Market by Disease Type
4.2.2 United States Blood Cancer Market by Type of Therapy: Forecast to 2028
4.3 EU5 Blood Cancer Market Forecast to 2028
4.3.1 EU5 Blood Cancer Market by Disease Type
4.3.2 EU5 Blood Cancer Market Forecast by Type of Therapy: Forecast to 2028
4.3.3 EU5 Blood Cancer Market by Country Share, 2018 and 2028
4.4 BRIC Blood Cancer Market Forecast to 2028
4.4.1 BRIC Blood Cancer Market by Disease Type
4.4.2 BRIC Blood Cancer Market by Type of Therapy: Forecast to 2028
4.4.3 BRIC Countries Blood Cancer Market
4.4.3.1 Brazil
4.4.3.2 India
4.4.3.3 Russia
4.4.3.4 China
4.4 Japan Blood Cancer Market Forecast to 2028
4.4.1 Japan Blood Cancer Market: by Disease Type
4.4.2 Japan Blood Cancer Market by Type of Therapy: Forecast to 2028

5. Leading Companies in the Blood Cancer Market
5.1 Introduction
5.1.1 Amgen Inc.
5.1.1.1 Business Overview
5.1.1.2 Recent Financials
5.1.1.3 Product Offerings
5.1.1.4 Recent developments
5.1.2 AstraZeneca PLC
5.1.2.1 Business Overview
5.1.2.2 Recent Financials
5.1.2.3 Product Offerings
5.1.2.4 Recent developments
5.1.3 Bayer AG
5.1.3.1 Business Overview
5.1.3.2 Recent Financials
5.1.3.3 Product Offerings
5.1.3.4 Recent developments
5.1.4 Bristol-Myers Squibb Company
5.1.4.1 Business Overview
5.1.4.2 Recent Financials
5.1.4.3 Product Offerings
5.1.4.4 Recent developments
5.1.5 Celgene Corporation
5.1.5.1 Business Overview
5.1.5.2 Recent Financials
5.1.5.3 Product Offerings
5.1.5.4 Recent developments
5.1.6 Roche
5.1.6.1 Business Overview
5.1.6.2 Recent Financials
5.1.6.3 Product Offerings
5.1.6.4 Recent developments
5.1.7 Johnson & Johnson
5.1.7.1 Business Overview
5.1.7.2 Recent Financials
5.1.8 Novartis
5.1.8.1 Business Overview
5.1.8.2 Recent Financials
5.1.8.3 Product Offerings
5.1.8.4 Recent developments
5.1.9 Pfizer Inc.
5.1.9.1 Business Overview
5.1.9.2 Recent Financials
5.1.9.3 Product Offerings
5.1.9.4 Recent Developments

6. Blood Cancer: R&D Pipeline
6.1 Blood Cancer: R&D Pipeline
6.1.1 Drugs for Leukemia
6.1.2 Drugs for Lymphoma
6.1.3 Multiple Myeloma
6.1.4 Other Major Drugs Under Different Stages of Development

7. Qualitative Analysis
7.1. Porter’s Five Forces Analysis
7.1.1. Bargaining power of buyers (MEDIUM)
7.1.2 Bargaining power of suppliers (LOW)
7.1.3 Industry rivalry (HIGH)
7.1.4 Threat of new entrants
7.1.5 Threat of substitutes (HIGH)
7.2 Market Dynamics of Blood Cancer Market
7.2.1 Trends
7.2.2 Drivers
7.2.3 Challenges

8. Conclusions & Recommendations
8.1 Key Takeaway
8.2 Conclusion

Appendices

List of Tables


Table 2.1 Incident Cases of Leukaemia by Country: 2018-2028
Table 2.2 Incident cases of Non-Hodgkin Lymphoma (NHL) by Country: 2018-2028
Table 2.3 Incident Cases of Hodgkin Lymphoma (HL) by Country: 2018-2028
Table 2.4 Incident cases of Multiple Myeloma by Country: 2018-2028
Table 3.1 Global Blood Cancer Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2028
Table 3.2 Global Chemotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CARG (%), 2018-2028
Table 3.3 Global Targeted Therapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 3.4 Global Immunotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.1 United States Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.2 Incident Cases of Different Types of Cancers in the US: 2018-2028
Table 4.3: United States Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), AGR (%), CAGR (%)
Table 4.4 EU5 Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.5 Incident Cases of Different Types of Cancers in the EU5
Table 4.6 EU5 Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), AGR (%), CAGR (%)
Table 4.7 BRIC Blood Cancer Market Forecast 2018-2028 by Country: Revenue ($bn), AGR (%), CAGR (%)
Table 4.8 Incident Cases of Different Types of Cancers in BRIC Countries: 2018-2028
Table 4.9 BRIC Countries Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), 2018-2028
Table 4.10 Japan Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
Table 4.11 Incident Cases of Different Types of Cancers in Japan: 2018-2028
Table 4.12 Japan Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), 2018-2028
Table 5.1 Amgen Inc.: Key Facts
Table 5.2 Amgen Inc.: Financial Information 2016-2017
Table 5.3 AstraZeneca PLC: Key Facts
Table 5.4 AstraZeneca PLC: Financial Information 2016-2017
Table 5.5 Bayer AG: Key Facts
Table 5.6 Bayer AG: Recent Financials 2016-2017
Table 5.7 Bristol-Myers Squibb Company – Key Facts
Table 5.8 Bristol-Myers Squibb: Recent Financials 2016-2017
Table 5.9 Celgene Corporation: Key Facts
Table 5.10 Celgene: Recent Financials 2016-2017
Table 5.11 Roche: Key Facts
Table 5.12 Roche: Recent Financials 2016-2017
Table 5.13 Johnson & Johnson: Key Facts
Table 5.14 Johnson & Johnson: Recent Financials 2016-2017
Table 5.15 Novartis AG: Key Facts
Table 5.16 Novartis: Recent Financials 2016-2017
Table 5.17 Pfizer Inc.: Key Facts
Table 5.18 Pfizer Inc.: Recent Financials 2016-2017
Table 6.1 Major Drugs Udder Development

List of Figures


Figure 2.1 Types of Blood Cancer
Figure 2.2 Different Types of Leukaemia
Figure 2.3 Trend of Leukaemia Cases by Country: 2018-2028
Figure 2.4 Trend of Non-Hodgkin Lymphoma (NHL) by Country: 2018-2028
Graph 2.5 Trend of Hodgkin Lymphoma (NHL) by Country: 2018-2028
Figure 2.6 Trend of Multiple Myeloma by Country: 2018-2028
Figure 3.1 Market Size of Cancer Therapy by Type ($bn): 2018-2028
Figure 3.2 Market share (%) of Cancer Therapy by Type: 2018 and 2028
Figure 3.3: Global Chemotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 3.4 Global Targeted Therapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 3.5 Global Immunotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 4.1 Blood Cancer Market by Region: % Share, 2018
Figure 4.2 Blood Cancer Market by Region: % Share, 2028
Figure 4.3: United States Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 4.4: Distribution of Different Types of Blood Cancer in the US: 2018-2028
Figure 4.5: EU5 Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 4.6 EU5 Blood Cancer Market by Country: % Share, 2018 and 2028
Figure 4.7: BRIC Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 4.8: Japan Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
Figure 4.9: Distribution of Different Types of Blood Cancer in Japan: 2018-2028
Figure 8.1: Global Blood Cancer Market by Region: Revenue ($bn), 2018
Figure 8.2: Global Blood Cancer Market by Region: Revenue ($bn), 2018